Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital de Bicêtre, 78 rue du Général Leclerc, F-94275 Le Kremlin-Bicêtre, France.
J Clin Endocrinol Metab. 2012 Jun;97(6):2124-33. doi: 10.1210/jc.2011-3188. Epub 2012 Apr 10.
Hypercalciuria is frequent in patients with acromegaly, but it is unclear how GH/IGF-I regulate renal calcium handling. Elevated fasting plasma calcium levels despite increased glomerular filtration suggest enhanced renal calcium reabsorption.
The aim of this study was to investigate the impact of acromegaly on phosphocalcium metabolism.
We conducted a prospective sequential study at a tertiary referral medical center and clinical investigation center (www.ClinicalTrials.gov Identifier: NCT00531908).
Sixteen consecutive patients (five females/11 males) with acromegaly received a single iv infusion of 25 mg of furosemide to induce an acute increase in calcium and magnesium delivery to distal tubular segments during a high-sodium diet with stable dietary calcium, magnesium, and phosphate intake.
Baseline plasma and urine electrolytes, plasma calciotropic hormones, and furosemide-induced changes in the fractional excretion and tubular reabsorption of Na, Ca, and Mg were measured before and 6 months (range, 1-12) after effective treatment of acromegaly.
Serum IGF-I concentrations normalized in all the patients after acromegaly treatment. Compared with controlled acromegaly, active acromegaly was associated with higher fasting plasma (P = 0.0002) and urinary calcium (P = 0.0003) levels, lower PTH levels (P = 0.0075), higher calcitriol levels (P = 0.0137), higher phosphatemia (P<0.0001) and tubular phosphate reabsorption (P = 0.0002), and a lower calciuric (P = 0.0327) but not magnesiuric response to furosemide related to higher baseline and postfurosemide tubular calcium (P = 0.0034 and P = 0.0081, respectively), but not magnesium reabsorption.
The IGF-I-mediated and PTH-independent increase in calcitriol synthesis in acromegaly is responsible for both absorptive hypercalciuria and increased fasting plasma calcium linked to enhanced distal tubular calcium reabsorption, as shown by the selectively diminished calciuric response to furosemide.
肢端肥大症患者常伴有高钙尿症,但 GH/IGF-I 如何调节肾脏钙处理尚不清楚。尽管肾小球滤过率增加,空腹血浆钙水平仍升高,提示肾脏钙重吸收增强。
本研究旨在探讨肢端肥大症对磷钙代谢的影响。
我们在一家三级转诊医疗中心和临床研究中心(www.ClinicalTrials.gov 标识符:NCT00531908)进行了一项前瞻性连续研究。
16 例连续肢端肥大症患者(女性 5 例/男性 11 例)接受单次静脉注射 25mg 呋塞米,在高钠饮食时,稳定的饮食钙、镁和磷摄入,以诱导钙和镁向远端肾小管段的急性输送增加。
在肢端肥大症有效治疗前和 6 个月(范围 1-12 个月)后,测量基础血浆和尿液电解质、血浆钙调节激素以及呋塞米诱导的 Na、Ca 和 Mg 排泄分数和肾小管重吸收的变化。
所有患者的 IGF-I 浓度在肢端肥大症治疗后均正常化。与控制良好的肢端肥大症相比,活动期肢端肥大症患者空腹血浆(P = 0.0002)和尿钙(P = 0.0003)水平更高,PTH 水平更低(P = 0.0075),活性维生素 D 水平更高(P = 0.0137),血磷水平更高(P<0.0001),肾小管磷重吸收更高(P = 0.0002),钙排泄率较低(P = 0.0327),但呋塞米诱导的镁排泄率无差异,与较高的基础值和呋塞米后肾小管钙相关(P = 0.0034 和 P = 0.0081),但与镁重吸收无关。
肢端肥大症中 IGF-I 介导的和 PTH 独立的活性维生素 D 合成增加导致吸收性高钙尿症和空腹血浆钙升高,这与增强的远端肾小管钙重吸收有关,如呋塞米诱导的钙排泄率选择性降低所示。